Zynerba Pharmaceuticals Inc $ 3.58 0 (0%)
Warning! GuruFocus has detected 2 Severe warning signs with ZYNE. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Zynerba Pharmaceuticals Inc () from 2015 to Jan 24 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Zynerba Pharmaceuticals stock (ZYNE) PE ratio as of Jan 24 2021 is 0. More Details
Zynerba Pharmaceuticals PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Zynerba Pharmaceuticals PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:EOLS OTCPK:CXRXF NAS:RMTI NAS:SLDB NAS:HROW NAS:ACRX NAS:KIN OTCPK:CVSI AMEX:XXII NAS:REPH NYSE:ZTS TSE:4502 XTER:MRK HKSE:03692 TSE:4523 SZSE:000661 TSE:4507 SZSE:000538 NSE:SUNPHARMA SZSE:300601
Address 80 West Lancaster Avenue, Suite 300, Devon, PA, USA, 19333
Zynerba Pharmaceuticals Inc together with its subsidiary is a pharmaceutical company which is focused on developing and commercializing proprietary next generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates are ZYN001 and ZYN002. The company has initiated a clinical trial for both the product candidates.